bullish

Wuxi Biologics Placement - Laying the Groundwork for Future Growth

391 Views02 Feb 2021 19:24
Wuxi Biologics (2269 HK) is looking to raise US$1.3bn in its primary placement to fund  acquisitions and expand capacity. This is the company's 13th placement since it listed in June 2017.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
x